1
2
Bos, J.M., Rumke, H.C., Welte, R., Spanjaard, L., van Alphen, L., Postma, M.J.
Veröffentlicht in: Bos , J M , Rumke , H C , Welte , R , Spanjaard , L , van Alphen , L & Postma , M J 2006 , ' Combination vaccine against invasive meningococcal B and pneumococcal infections - Potential epidemiological and economic impact in The Netherlands ' , Pharmacoeconomics , vol. 24 , no. 2 , pp. 141-153 .;
2006
Veröffentlicht in: Bos , J M , Rumke , H C , Welte , R , Spanjaard , L , van Alphen , L & Postma , M J 2006 , ' Combination vaccine against invasive meningococcal B and pneumococcal infections - Potential epidemiological and economic impact in The Netherlands ' , Pharmacoeconomics , vol. 24 , no. 2 , pp. 141-153 .;
2006
3
Hubben, G.A.A., Bos, J.M., Glynn, D.M., van der Ende, A., van Alphen, L., Postma, M.J.
Veröffentlicht in: Hubben , G A A , Bos , J M , Glynn , D M , van der Ende , A , van Alphen , L & Postma , M J 2007 , ' Enhanced decision support for policy makers using a web interface to health-economic models - Illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands ' , Vaccine , vol. 25 , no. 18 , pp. 3669-3678 . https://doi.org/10.1016/j.vaccine.2007.01.088;
2007
Veröffentlicht in: Hubben , G A A , Bos , J M , Glynn , D M , van der Ende , A , van Alphen , L & Postma , M J 2007 , ' Enhanced decision support for policy makers using a web interface to health-economic models - Illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands ' , Vaccine , vol. 25 , no. 18 , pp. 3669-3678 . https://doi.org/10.1016/j.vaccine.2007.01.088;
2007
4
Bos, J.M., Rietveld, E., Moll, HA, Steyerberg, E.W., Luytjes, W., Wilschut, J.C., de Groot, R., Postma, M.J.
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
5
6
7